Drug Trial Radar · NCT05762146
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
Last checked: Nov 20, 2026Latest source record: Oct 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28
Planned (sponsor's estimate)
Start
Sep 5, 2022
Primary completion
Feb 29, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Maastricht UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A combination therapy proposed to be evaluated in this trial, consisting of three already registered compounds with a validated disease mechanism and with known safety profiles, targets key proteins in the dysregulated signal network in stroke, and is expected to synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection. The synergistic mode of action will allow for low doses and is expected to reduce possible side effects while maintaining maximal efficacy
Conditions
- Ischemic Stroke, Acute
Interventions
RiociguatDrug
Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
PropylthiouracilDrug
Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
PerphenazineDrug
Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SICH as per ECASS IIITime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Essen, Department of Neurology
Essen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.